CRISPR and KRAS: a match yet to be made

Area of Science:

• Molecular biotechnology
• Genomics
• Oncology

Background:

• KRAS mutations are key drivers in lung, colorectal, and pancreatic cancers, lacking effective treatments.
• CRISPR (clustered regularly interspaced short palindromic repeats) systems offer novel genome editing capabilities.
• Targeting KRAS mutations presents a significant challenge in cancer therapy.

Purpose of the Study:

• To review CRISPR applications for targeting KRAS mutations and related molecules in cancer.
• To highlight CRISPR's potential in treating KRAS-driven lung, colorectal, and pancreatic cancers.
• To assess the current progress and future directions of CRISPR-based KRAS-targeted therapies.

Main Methods:

• Literature review of studies employing CRISPR systems against KRAS mutations.
• Analysis of CRISPR applications targeting KRAS directly and its related signaling pathways.
• Focus on preclinical and in vitro/in vivo studies in relevant cancer models.

Main Results:

• CRISPR targeting of mutant KRAS variants reduced cancer cell viability and proliferation in vitro.
• In vivo studies demonstrated CRISPR-mediated inhibition of tumor growth.
• CRISPR knockdown of mutant KRAS influenced downstream effectors like PI3K, ERK, Akt, Stat3, and c-myc.

Conclusions:

• CRISPR technology shows promising therapeutic potential for KRAS-mutated cancers.
• Further research is needed to develop effective CRISPR-based treatment strategies.
• CRISPR remains underutilized for KRAS mutations, highlighting a need for increased research efforts.